ZTS

Zoetis Inc

Add to Watchlist

Advanced Chart

152.120

-0.7(-0.458%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

153.370

Open

152.300

VWAP

152.03

Vol

3.33M

Mkt Cap

67.73B

Low

151.230

Amount

505.85M

EV/EBITDA(TTM)

18.44

Total Shares

456.30M

72.58B

EV/OCF(TTM)

24.65

P/S(TTM)

7.41

Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

2.44B

+5.41%

1.500

+7.17%

2.44B

+1.99%

1.654

+4.69%

2.41B

+1.91%

1.610

+3.21%

Estimates Revision

The market is revising Upward the revenue expectations for Zoetis Inc. (ZTS) for FY2025, with the revenue forecasts being adjusted by 1.71% over the past three months. During the same period, the stock price has changed by -0.94%.

Revenue Estimates for FY2025

Revise Upward

+1.71%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.92%

In Past 3 Month

Stock Price

Go Down

-0.94%

In Past 3 Month

9 Analyst Rating

23.42% Upside

Wall Street analysts forecast ZTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZTS is 187.75 USD with a low forecast of 160.00 USD and a high forecast of 210.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

2 Hold

0 Sell

Strong Buy

23.42% Upside

Current: 152.120

Low

160.00

Averages

187.75

High

210.00

23.42% Upside

Current: 152.120

Low

160.00

Averages

187.75

High

210.00

Leerink

Daniel Clark

Outperform -> Market Perform

downgrade

$155

2025-07-17

Reason

Leerink

Daniel Clark

Price Target

$155

2025-07-17

downgrade

Outperform -> Market Perform

Reason

Leerink analyst Daniel Clark downgraded Zoetis to Market Perform from Outperform with a $155 price target.

Leerink

Outperform -> Market Perform

downgrade

$180 -> $155

2025-07-17

Reason

Leerink

Price Target

$180 -> $155

2025-07-17

downgrade

Outperform -> Market Perform

Reason

Leerink downgraded Zoetis (ZTS) to Market Perform from Outperform with a price target of $155, down from $180. The firm is now less positive on the company's growth prospects over the next several years due to rising competition in the legacy dermatology business and a Librela launch "that appears to have lost momentum." Zoetis will launch new products and grow sales going forward, but at a slower rate when factoring in increased competition from Elanco Animal Health (ELAN) and Merck (MRK) in dermatology and parasiticides, the analyst tells investors in a research note. As such, it sees a more balanced risk/reward profile for the stock going forward.

Stifel

Jonathan Block

Buy

Hold

downgrade

$165 -> $160

2025-06-18

Reason

Stifel

Jonathan Block

Price Target

$165 -> $160

2025-06-18

downgrade

Buy

Hold

Reason

Piper Sandler

David Westenberg

Overweight

maintain

$205 -> $210

2025-05-12

Reason

Piper Sandler

David Westenberg

Price Target

$205 -> $210

2025-05-12

maintain

Overweight

Reason

Piper Sandler analyst David Westenberg raised the firm's price target on Zoetis to $210 from $205 following quarterly results. The firm keeps an Overweight rating on the shares.

Stifel

Jonathan Block

Strong Buy

Maintains

$180 → $165

2025-04-14

Reason

Stifel

Jonathan Block

Price Target

$180 → $165

2025-04-14

Maintains

Strong Buy

Reason

Stifel analyst Jonathan Block lowered the firm's price target on Zoetis to $165 from $180 and keeps a Buy rating on the shares following survey work focused on recent innovation from the major Animal Health players.

Piper Sandler

David Westenberg

Buy

Maintains

$200 → $205

2025-02-27

Reason

Piper Sandler

David Westenberg

Price Target

$200 → $205

2025-02-27

Maintains

Buy

Reason

Piper Sandler raised the firm's price target on Zoetis to $205 from $200 following the company's quarterly results. The firm keeps an Overweight rating on the shares.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Zoetis Inc (ZTS.N) is 23.99, compared to its 5-year average forward P/E of 33.45. For a more detailed relative valuation and DCF analysis to assess Zoetis Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

33.45

Current PE

23.99

Overvalued PE

39.16

Undervalued PE

27.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

23.19

Current EV/EBITDA

17.45

Overvalued EV/EBITDA

26.61

Undervalued EV/EBITDA

19.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

9.61

Current PS

7.02

Overvalued PS

11.12

Undervalued PS

8.10

Financials

Annual

Quarterly

FY2025Q1

YoY :

+1.37%

2.22B

Total Revenue

FY2025Q1

YoY :

+6.66%

849.00M

Operating Profit

FY2025Q1

YoY :

+5.34%

631.00M

Net Income after Tax

FY2025Q1

YoY :

+7.63%

1.41

EPS - Diluted

FY2025Q1

YoY :

-3.74%

438.00M

Free Cash Flow

FY2025Q1

YoY :

+2.17%

70.54

Gross Profit Margin - %

FY2025Q1

YoY :

+22.55%

24.56

FCF Margin - %

FY2025Q1

YoY :

+3.91%

28.42

Net Margin - %

FY2025Q1

YoY :

+3.65%

23.55

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

110.8K

USD

3-6

Months

312.3K

USD

6-9

Months

617.0K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 228.26% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

310.2K

Volume

6-9

Months

553.9K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

4.4M

Volume

Months

6-9

1.4M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

80.5K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

91.0K

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

110.8K

USD

3-6

Months

312.3K

USD

6-9

Months

617.0K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ZTS News & Events

Events Timeline

2025-05-06 (ET)

2025-05-06

07:15:17

Zoetis raises FY25 EPS view to $6.20-$6.30 from $6.00-$6.10, consensus $6.06

2025-05-06

07:13:36

Zoetis reports Q1 EPS $1.48, consensus $1.40

2025-02-14 (ET)

2025-02-14

13:01:58

Zoetis reports conditional license from USDA for Avian Influenza Vaccine

News

5.0

07-25NASDAQ.COM

Billionaire Terry Smith Sold Fundsmith's Entire Stake in Apple and 11X'd His Position in a Company Whose Addressable Market Can Hit $149 Billion by 2032

8.0

07-24NASDAQ.COM

Notable Thursday Option Activity: ZTS, WFC, BROS

3.0

07-21Yahoo Finance

Veterinary Dermatology - Company Evaluation Report 2025 | Zoetis, Elanco, and Boehringer Ingelheim Dominate with Global Reach, Innovative Portfolios, and Strategic Expansion